Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast

BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 17, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022 .